Sanofi Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (70)

Latest Posts

About This Stock More About This Stock
Week In Review: Another Billion Dollar Week For China Life Science Deals
Article By: ChinaBio® Today
Saturday, September 30, 2017 5:55 PM EDT
Shanghai Pharma Holding (SHA: 601607) may acquire part of Alvogen -- possibly Alvogen's US operations -- according to Bloomberg. Alvogen is a US-based generic drug maker thought to be worth as much as $4 billion.
In this article: NVO, SNY, SVA, AMGN, GILD, ZLAB, TSRO
Read
Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints
Article By: Zacks Investment Research
Monday, September 11, 2017 4:50 PM EDT
Regeneron Pharmaceuticals, Inc. and partner Sanofi announced that Dupixent (dupilumab) met its two primary endpoints in a phase III study conducted on patients with uncontrolled, persistent asthma.
In this article: SNY, REGN Also: ALXN, ADRO
Read
Forget Teva, Buy These 4 Drug Stocks Instead
Article By: Arpita Dutt
Friday, August 11, 2017 1:17 PM EDT
It’s not been a good quarter for Israel-based generic drug maker, Teva Pharmaceutical Industries Limited. Teva missed on both second quarter earnings and revenues and lowered its outlook for 2017.
In this article: SNY, ALXN, REGN, GILD, TEVA
Read
Bayer (BAYRY) Q2 Earnings Beat, Sales Miss, Cuts Guidance
Article By: Zacks Investment Research
Thursday, July 27, 2017 10:00 AM EDT
Bayer AG’s second-quarter 2017 core earnings per share from continuing operations was $1.99. Earnings were down 12.7% year over year from $2.28 per share.
In this article: ENZ, MON, SNY, BAYRY
Read
3 Large Cap Pharma Stocks To Buy Now
Article By: Zacks Investment Research
Monday, June 12, 2017 3:59 PM EDT
The healthcare sector has dominated headlines this year thanks to promises from the GOP and the Trump administration related to repealing and replacing Obamacare.
In this article: SNY, BAYRY, HLUYY
Read

PARTNER HEADLINES

Latest Tweets for $SNY

No tweets yet!